{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:08:36Z","timestamp":1780045716324,"version":"3.53.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.humpath.2026.106123","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:27:00Z","timestamp":1776011220000},"page":"106123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5701-0857","authenticated-orcid":false,"given":"Chuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody J.","family":"Artymiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya L.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen D.","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Viswanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106123_bib1","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib2","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2026.106123_bib4","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106123_bib5","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/imr.12745","article-title":"Molecular pathogenesis of germinal center-derived B cell lymphomas","volume":"288","author":"Pasqualucci","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.humpath.2026.106123_bib7","article-title":"Haematolymphoid tumours","volume":"11","year":"2024"},{"key":"10.1016\/j.humpath.2026.106123_bib8","series-title":"The international consensus classification of Myeloid and Lymphoid Neoplasms","author":"Daniel Arber","year":"2025"},{"key":"10.1016\/j.humpath.2026.106123_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.humpath.2026.106123_bib10","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106123_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","article-title":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY","volume":"37","author":"Mansouri","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106123_bib12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ajh.25831","article-title":"Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index","volume":"95","author":"Kleinstern","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106123_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2026.106123_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-Mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106123_bib16","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106123_bib17","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2024025652","article-title":"DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma","volume":"145","author":"Chapuy","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2026.106123_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2026.106123_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17132","article-title":"Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL)","volume":"192","author":"Runge","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2026.106123_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib22","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/modpathol.2017.58","article-title":"Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms","volume":"30","author":"Onaindia","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106123_bib23","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2026.106123_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12185-025-04065-2","article-title":"Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma","volume":"122","author":"Kanemasa","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.humpath.2026.106123_bib25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2026.106123_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41392-025-02316-6","article-title":"Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)","volume":"10","author":"Shen","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.humpath.2026.106123_bib27","series-title":"Genotype-guided treatment in DLBCL. clinicalTrials.gov ID NCT05351346","author":"Weili Zhao","year":"2022"},{"key":"10.1016\/j.humpath.2026.106123_bib28","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1080\/10428194.2020.1786560","article-title":"Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience","volume":"61","author":"Pillonel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2026.106123_bib29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41379-020-00720-7","article-title":"Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice","volume":"34","author":"Davis","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106123_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ajcp\/aqaa255","article-title":"Clinical utility of targeted next-generation sequencing in the evaluation of low-grade lymphoproliferative disorders","volume":"156","author":"Jajosky","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2026.106123_bib31","article-title":"Diagnostic implications of NGS-based molecular profiling in mature B-Cell lymphomas with potential bone marrow involvement","volume":"15","author":"Strasser","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.humpath.2026.106123_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1231601","article-title":"Targeted panel sequencing in the routine diagnosis of mature T- and NK-cell lymphomas: report of 128 cases from two German reference centers","volume":"13","author":"B\u00f6ck","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2026.106123_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jmoldx.2024.03.008","article-title":"Clinical validation of a targeted next-generation sequencing panel for lymphoid malignancies","volume":"26","author":"Artymiuk","year":"2024","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106123_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000169","article-title":"The need for a consensus next-generation sequencing panel for mature lymphoid malignancies","volume":"3","author":"Sujobert","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.humpath.2026.106123_bib35","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.humpath.2026.106123_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.humpath.2026.106123_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40291-021-00540-8","article-title":"Internal standardization of the interpretation and reporting of sequence variants in hematologic neoplasms","volume":"25","author":"Mehta","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.humpath.2026.106123_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00428-022-03487-1","article-title":"Advances in the classification of myeloid and lymphoid neoplasms","volume":"482","author":"Arber","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2026.106123_bib40","unstructured":"National Comprehensive Cancer Network (NCCN) guidelines on B cell lymphomas, chronic lymphocytic leukemia\/small lymphocytic lymphoma, and T cell lymphoma. https:\/\/www.nccn.org\/guidelines\/category_1."},{"key":"10.1016\/j.humpath.2026.106123_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2026.106123_bib42","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.humpath.2026.106123_bib43","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2026.106123_bib44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106123_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106123_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689472","article-title":"Resistance mutations to BTK inhibitors originate from the NF-\u03baB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.humpath.2026.106123_bib47","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106123_bib48","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib49","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2026.106123_bib50","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2022-168002","article-title":"Mutations of ATM confer a risk of inferior survival in patients with TP53-wild type mantle cell lymphoma","volume":"140","author":"Koff","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib51","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib52","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106123_bib53","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.2023021790","article-title":"A modern view of LGL leukemia","volume":"144","author":"Marchand","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1309\/8QYTYQ1CLQMHQ9CL","article-title":"Hairy cell leukemia variant: fact or fiction","volume":"123","author":"Cessna","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2026.106123_bib55","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood.2021013502","article-title":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors","volume":"139","author":"Falini","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib56","article-title":"A study of vemurafenib and obinutuzumab compared to cladribine and rituximab in people with Hairy Cell Leukemia (HCL)","author":"Jae Park","year":"2024","journal-title":"ClinicalTrials"},{"key":"10.1016\/j.humpath.2026.106123_bib57","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood-2024-204016","article-title":"Non-V600E BRAF gene alterations in hairy cell leukemia","volume":"144","author":"Arons","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2026.106123_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100519","article-title":"Clonal hematopoiesis and bone marrow infiltration in patients with follicular helper T-Cell lymphoma of angioimmunoblastic type","volume":"37","author":"Harland","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106123_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/gcc.22141","article-title":"Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia","volume":"53","author":"Bergmann","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2026.106123_bib61","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106123_bib62","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(09)70351-1","article-title":"Common misdiagnoses in lymphomas and avoidance strategies","volume":"11","author":"Chan","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2026.106123_bib63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5858\/arpa.2020-0261-SA","article-title":"Laboratory workup of lymphoma in adults: guideline from the American society for clinical pathology and the college of American pathologists","volume":"145","author":"Kroft","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2026.106123_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14796694.2024.2430725","article-title":"Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey","volume":"21","author":"Hussain","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.humpath.2026.106123_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.5785","article-title":"Claim denials for cancer-related next-generation sequencing in medicare","volume":"8","author":"Kang","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726000924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726000924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:23:56Z","timestamp":1780043036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726000924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":65,"alternative-id":["S0046817726000924"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106123","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106123"}}